<DOC>
	<DOCNO>NCT00492570</DOCNO>
	<brief_summary>This study do increase awareness early therapy Avonex Multiple Sclerosis ( MS ) cognitive dysfunction accompanies MS , record safety data Avonex .</brief_summary>
	<brief_title>GER-009-06-AVX Early Therapy Multiple Sclerosis</brief_title>
	<detailed_description>This study address cognitive dysfunction associate MS . It track change show early intervention Avonex effective slow MS effect patient . Safety data also collect study .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis , Relapsing-Remitting</mesh_term>
	<criteria>CIS ( accord indication ) early Relapsing Remitting Multiple Sclerosis treatment DMT last 12 month</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2009</verification_date>
	<keyword>Multiple Sclerosis</keyword>
	<keyword>Cognitive Dysfunction Multiple sclerosis</keyword>
	<keyword>early treatment</keyword>
	<keyword>Avonex</keyword>
	<keyword>interferon beta 1a</keyword>
	<keyword>Cognitive Dysfunction</keyword>
</DOC>